Hematopoietic stem cells (HSCs) are the precursor cells for a variety of blood cells. Because of their self-renewal properties, these cells have been used in transplantation to treat patients with cancers and other disorders related to the blood and immune system. In recent studies, these cells have been implicated for their potential to become cell types other than the blood cells, widening their promise in biomedical applications. To date, the process of identifying and purifying HSCs from the bone marrow remains a technical challenge. This process depends on cell markers that are specifically and uniquely expressed on HSCs, but because only a few highly specific HSC markers have been identified, isolation of HSCs do not yield desirable purity, limiting their clinical use.
Researchers at the University of Michigan have developed a new method for identifying and collecting HSCs and compositions highly enriched for HSCs. Specifically, this method is based on the presence or absence of particular Signaling lymphocyte activation molecule (SLAM) family member proteins, CD150, CD48, and CD244. This technology is available only on a non-exclusive basis.
Applications and Advantages
- Any applications in which HSCs, or the-nl-identification thereof, are useful, including-nl-but not limited to transplantation,-nl-identification and quantification of HSCs in-nl-tissue transplants, monitoring the progress-nl-of transplantation or chemotherapeutic treatment
- Method can be adopted to currently used-nl-separation techniques and bioassays for-nl-identification, quantification or physical separation